This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Dr Badve is a well ...
This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Now, if ever there ...
OnkoBank: A clinically annotated cancer biobank supporting translational and precision oncology research. This is an ASCO Meeting Abstract from the 2026 ASCO Annual Meeting I. This abstract does not ...
Integrating HER2-directed therapies into NSCLC decision-making requires adapting protocols and ensuring timely updates as new therapies emerge. Streamlined processes and enhanced communication among ...
CHICAGO--(BUSINESS WIRE)--Tempus, a leader in artificial intelligence and precision medicine, announced new testing solutions to help physicians identify patients with HER2 or FOLR1 expressing tumors, ...
HER2-directed therapies, including monoclonal antibodies, ADCs, and TKIs, have improved survival in HER2-positive breast cancer patients. Clinical trials like CLEOPATRA, DESTINY-Breast01, and ...
"Medical Journeys" is a set of clinical resources reviewed by physicians, meant for the medical team as well as the patients they serve. Each episode of this journey through a disease state contains ...
Patients with stage I HER2-positive breast cancer treated with rastuzumab emtansine (T-DM1) had beneficial long-term outcomes with a 5-year disease-free survival rate of 97%, with the HER2DX score ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results